CompletedPhase 4

Clinical Evaluation of Furocyst in Patients With Poly Cystic Ovary Syndrome

50 participantsStarted 2013-09

Plain-language summary

Poly cystic ovary syndrome (PCOS) is a disease which is prevalent in women of reproductive age facing obesity along with increased risk of type-2 diabetes and high cholesterol levels. The genetically determined cause of the PCOS includes disturbed levels of insulin and androgens. Standardized fenugreek seed extract (Furocyst) contains compounds such as saponins \& flavonoids which act on the insulin and indirectly helps to regulate the androgen levels in the body.

Who can participate

Age range18 Years – 45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Premenopausal women between 18-45 years of age and BMI less than 42 * Diagnosed with PCOS * Adequate hepatic, renal and hematological functions * Patients willing to give informed consent in writing Exclusion Criteria: * Males * Post menopausal women * Women with hysterectomy * Patients with congenital adrenal hyperplasia * Patients suffering from Cushing's syndrome * Patients diagnosed with androgen secreting tumors * Patients with thyroid dysfunction (T3, T4 level is higher than that in normal women of reproductive age) * Patients with Hypo-gonadotropic and Hypo-gonadism (central origin of ovarian dysfunction) * Pregnancy or desire for pregnancy or lactating mothers

What they're measuring

Reduction in Ovary volume as assessed by ultrasound

Timeframe: 12 weeks

Trial details

NCT IDNCT02789488

SponsorChemical Resources

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2014-07

View on ClinicalTrials.gov More Poly Cystic Ovary Syndrome trials